The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies

被引:0
|
作者
Guo, Haochuan [1 ]
Xu, Xinru [1 ]
Zhang, Jiaxi [1 ]
Du, Yajing [1 ]
Yang, Xinbing [1 ]
He, Zhiheng [2 ,3 ]
Zhao, Linjie [2 ,3 ]
Liang, Tingming [1 ]
Guo, Li [2 ,3 ]
机构
[1] Nanjing Normal Univ, Sch Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing 210023, Peoples R China
[2] Nanjing Univ Posts & Telecommun, State Key Lab Organ Elect & Informat Displays, 9 Wenyuan Rd, Nanjing 210023, Peoples R China
[3] Nanjing Univ Posts & Telecommun, Inst Adv Mat IAM, 9 Wenyuan Rd, Nanjing 210023, Peoples R China
基金
中国国家自然科学基金;
关键词
preclinical animal models; anti-cancer therapy; drug development; personalized therapy; REPEAT-DOSE TOXICITY; MOUSE MODELS; GENOMIC INSTABILITY; CYNOMOLGUS MONKEY; CARCINOGENICITY; HALLMARKS; SAFETY; REQUIREMENTS; GENERATION; CHALLENGES;
D O I
10.3390/ph17081048
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The establishment and utilization of preclinical animal models constitute a pivotal aspect across all facets of cancer research, indispensably contributing to the comprehension of disease initiation and progression mechanisms, as well as facilitating the development of innovative anti-cancer therapeutic approaches. These models have emerged as crucial bridges between basic and clinical research, offering multifaceted support to clinical investigations. This study initially focuses on the importance and benefits of establishing preclinical animal models, discussing the different types of preclinical animal models and recent advancements in cancer research. It then delves into cancer treatment, studying the characteristics of different stages of tumor development and the development of anti-cancer drugs. By integrating tumor hallmarks and preclinical research, we elaborate on the path of anti-cancer drug development and provide guidance on personalized cancer therapy strategies, including synthetic lethality approaches and novel drugs widely adopted in the field. Ultimately, we summarize a strategic framework for selecting preclinical safety experiments, tailored to experimental modalities and preclinical animal species, and present an outlook on the prospects and challenges associated with preclinical animal models. These models undoubtedly offer new avenues for cancer research, encompassing drug development and personalized anti-cancer protocols. Nevertheless, the road ahead continues to be lengthy and fraught with obstacles. Hence, we encourage researchers to persist in harnessing advanced technologies to refine preclinical animal models, thereby empowering these emerging paradigms to positively impact cancer patient outcomes.
引用
收藏
页数:30
相关论文
共 50 条
  • [1] PET in anti-cancer drug development and therapy
    Kumar, Rakesh
    Lal, Neena
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2007, 2 (03) : 259 - 263
  • [2] Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery
    Powley, Ian R.
    Patel, Meeta
    Miles, Gareth
    Pringle, Howard
    Howells, Lynne
    Thomas, Anne
    Kettleborough, Catherine
    Bryans, Justin
    Hammonds, Tim
    MacFarlane, Marion
    Pritchard, Catrin
    BRITISH JOURNAL OF CANCER, 2020, 122 (06) : 735 - 744
  • [3] THE USE OF ANIMAL-MODELS IN CANCER DRUG DISCOVERY AND DEVELOPMENT
    CURT, GA
    STEM CELLS, 1994, 12 (01) : 23 - 29
  • [4] Drug Repurposing: Exploring Potential Anti-Cancer Strategies by Targeting Cancer Signalling Pathways
    Haddad, Natalia
    Gamaethige, Sara Magura
    Wehida, Nadine
    Elbediwy, Ahmed
    BIOLOGY-BASEL, 2024, 13 (06):
  • [5] Skp1: Implications in cancer and SCF-oriented anti-cancer drug discovery
    Hussain, Muzammal
    Lu, Yongzhi
    Liu, Yong-Qiang
    Su, Kai
    Zhang, Jiancun
    Liu, Jinsong
    Zhou, Guang-Biao
    PHARMACOLOGICAL RESEARCH, 2016, 111 : 34 - 42
  • [6] Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?
    Prestwich, Robin J.
    Errington, Fiona
    Harrington, Kevin J.
    Pandha, Hardev S.
    Selby, Peter
    Melcher, Alan
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2008, 2 : 83 - 96
  • [7] Targeting EBV Episome for Anti-Cancer Therapy: Emerging Strategies and Challenges
    Sugiokto, Febri Gunawan
    Li, Renfeng
    VIRUSES-BASEL, 2025, 17 (01):
  • [8] Mitosis as an anti-cancer drug target
    Anna-Leena Salmela
    Marko J. Kallio
    Chromosoma, 2013, 122 : 431 - 449
  • [9] Mitosis as an anti-cancer drug target
    Salmela, Anna-Leena
    Kallio, Marko J.
    CHROMOSOMA, 2013, 122 (05) : 431 - 449
  • [10] Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
    Ladin, Daniel A.
    Soliman, Eman
    Griffin, LaToya
    Van Dross, Rukiyah
    FRONTIERS IN PHARMACOLOGY, 2016, 7